US IPO Week Ahead: A pivotal week with 8 IPOs
Eight deals are on the calenda.....»»
US IPO Week Ahead: A pivotal week with 8 IPOs
Eight deals are on the calenda.....»»
The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs
Biotech stocks reversed course in the week ended April 16, with the sector re.....»»
The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight
Biopharma stocks advanced in the week ended Feb. 5, driven higher by a slew of catalysts. Large-cap pharma earnings, vaccine updates, M&A activity, IPO news flow and follow-on offerings all served to lift stocks higher. read more.....»»
The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight
Biopharma stocks advanced in the week ended Feb. 5, driven higher by a slew of catalysts. Large-cap pharma earnings, vac.....»»
The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna"s COVID Vaccine And Drugs From Amgen, MacroGenics
Biotech stocks advanced for a third straight week, defying the broader market weakness. The space got solid support from positive stock reactions to presentations made at hematology and breast cancer conferences. read more.....»»
The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck
Notwithstanding the ESMO conference generating some huge moves in some stocks, last week turned out to be a muted one for biotechs. read more.....»»
The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear
Biotech stocks came under selling pressure in the week ended Sept. 27 amid clinical data readouts and a handful of FDA decisions. read more.....»»
Jim Cramer"s week ahead: We need more downside before I"m ready to get more positive
Overbought markets "tend to get hit with sell-offs, especially when we're being flooded with shoddy IPOs," Jim Cramer says......»»
The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck
Biotech stocks rebounded in last week after declining modestly in the previous week. read more.....»»
U.S. IPO Week Ahead: Summer"s Last Wave With 5 IPOs
U.S. IPO Week Ahead: Summer"s Last Wave With 5 IPOs.....»»
U.S. IPO Week Ahead: A Flurry Of IPOs Expected To Launch July Roadshows
U.S. IPO Week Ahead: A Flurry Of IPOs Expected To Launch July Roadshows.....»»
U.S. IPO Week Ahead: A Biotech Wave Drives 7 IPOs While Slack Targets A Direct Listing
U.S. IPO Week Ahead: A Biotech Wave Drives 7 IPOs While Slack Targets A Direct Listing.....»»
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Biotech stocks staged a recovery this week after being in the red in the previous two weeks. read more.....»»
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Biotech stocks staged a recovery this week after being in the red in the previous two weeks. AbbVie Inc (NYSE: ABBV)'s psoriasis drug Skyrizi received FDA nod. The week also saw the release of strong quarterly earnings by big European pharma gian.....»»
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Biotech stocks are on track to extend their losses, bucking the positive broader market sentiment. The week saw Achaogen Inc (NASDAQ: AKAO) filing for Chapter 11 bankruptcy and negative clinical readouts .....»»
U.S. IPO Week Ahead: No IPOs But These 12 Deals Can Hop Back In After Easter
U.S. IPO Week Ahead: No IPOs But These 12 Deals Can Hop Back In After Easter.....»»
Cramer"s game plan: Overvalued IPOs can dim a positive earnings season
Jim Cramer breaks down the week ahead in earnings and stock trading......»»
Cramer: Overvalued IPOs can dim a positive earnings season
Jim Cramer breaks down the week ahead in earnuings and stock trading......»»
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. read more.....»»